Author

Bing Xia

Nanjing Forestry University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Chen CheniD· 1 shared Cunqi YeiD· 1 shared Di HuangiD· 1 shared Dongze Mo· 1 shared Fei ZhangiD· 1 shared Hai Xin SongiD· 1 shared Hanjie Zhang· 1 shared Hui WeiiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Chen ChenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetically Engineered Biomimetic Nanozymes Reprogram Immune Niches to Intercept Colitis-Carcinoma Transition

Qi Sun, Wanling Liu, Sijie Li, Xiwen Chen, Hanjie Zhang, Dongze Mo, Pinwen Zhou, Xiaomiao Cui, Di Huang, Bing Xia, Jingjing Zhang, Xinying Wang, Xiaoyu Wang, Hui Wei

This paper develops genetically engineered nanozymes that target immune niches to prevent colitis-associated colorectal cancer by reducing oxidative stress and immune cell infiltration.

bioRxiv · Mar 16, 2026 · PreprintBioengineering

Oncogenic EGFR rewires STING-TBK1 immune machinery to license DNA damage tolerance

Qin Shen, Mei Chen, Yidan Chen, Qian Zhang, Qingzhe Wu, Xinyuan Yu, Fei Zhang, Shengduo Liu, Chen Chen, Cunqi Ye, Qi Zhang, Xin‐Hua Feng, Hai Xin Song, Tingbo Liang, Penghong Song, , Pinglong Xu

This study reveals that oncogenic EGFR mutations exploit the STING-TBK1 immune pathway to enhance DNA damage repair and therapeutic resistance in NSCLC.

bioRxiv · Oct 20, 2025 · PreprintCancer Biology